echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Roche IL-6 receptor inhibitors have been approved for the first time in Asia for the treatment of optic neurospinal itis spectrum disorder.

    Roche IL-6 receptor inhibitors have been approved for the first time in Asia for the treatment of optic neurospinal itis spectrum disorder.

    • Last Update: 2020-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    NMOSD is a rare neurodegenerative central nervous system (CNS) autoimmune disease that affects hundreds of thousands of people worldwide. The main symptoms of
    patients are inflammatory lesions in the optic nerve and spinal cord.
    NMOSD patients often recur, and repeated attacks by the immune system on their own tissues can lead to progressive accumulation of nerve damage and disability.
    patients experience decreased vision, motor function and quality of life, and severe NMOSD seizures can lead to death.
    , there is no approved treatment for the disease.
    Although NMOSD is thought to be a disease caused by the entry of autoimmune antibodies targeting AQP4 into CNS, about one-third of patients do not have autoimmune antibodies that target AQP4.
    In recent years, inflammatory cytokine IL-6 is a new and important target in NMOSD pathology, which triggers inflammatory cascade reactions, leading to injury and disability. Enspryng, developed by
    Roche, is a fully humanized IL-6 receptor monoclonal antibody.
    it inhibits the IL-6 signaling pathway and inhibits the production of inflammation and the generation of autoimmune antibodies targeting AQP4.
    Enspryng is injected every four weeks, making it a convenient treatment option for patients and caregivers.
    the FDA has awarded the therapy breakthrough therapy.

    . Enspryng's approval in Japan is based on the results of two key Phase 3 clinical studies.
    they assessed the efficacy and safety of Enspryng as a monodrug therapy, and as an additional therapy other than standard care.
    results of the trial showed that patients treated with Enspryng single drug had a 55 percent lower risk of recurrence compared to the placebo group.
    , patients who received Enspryng monodrug with a 74 percent lower risk of recurrence in the subgroup of patients who carried AQP4 autoantibodies.
    SAkuraSky's results showed that patients who received Enspryng combined with standard therapy had a 62 percent lower risk of recurrence compared to the placebo group.
    patients who received Enspryng combined with standard therapy had a 79 percent lower risk of recurrence in subgroups carrying AQP4 autoantibodies.
    " today's approval is the first time Enspryng has been approved in Asia, providing a new treatment option for patients with NMOSD to reduce recurrence.
    these relapses can eventually lead to irreversible disabilities, including blindness and paralysis," said Dr. Levi Garraway, Roche's chief medical officer and head of global product development.
    "
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.